文献速递自身免疫性与大疱性皮肤病皮肤感染

天疱疮患者使用利妥昔单抗对比硫唑嘌呤或霉酚酸酯的感染风险:一项大规模全球队列研究

Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study.
PubMed 文献 · Br J Dermatol · 2023-01-01

这项全球人群队列研究通过倾向评分匹配比较了963例使用利妥昔单抗与963例使用硫唑嘌呤或霉酚酸酯的天疱疮患者的26种感染风险。利妥昔单抗组在治疗初始12个月内COVID-19、寄生虫病和巨细胞病毒感染风险升高,≥12个月后肺炎、COVID-19、骨髓炎、单纯疱疹病毒和巨细胞病毒感染风险仍较高。作者建议即使治疗1年后也应考虑肺炎球菌疫苗和抑制性抗病毒治疗。

要点

  • 利妥昔单抗组初始12个月内COVID-19、寄生虫病和巨细胞病毒感染风险升高。
  • 治疗≥12个月后利妥昔单抗仍与肺炎、COVID-19、骨髓炎、单纯疱疹病毒和巨细胞病毒感染风险升高相关。
  • 未观察到结核、乙型肝炎病毒再激活、耶氏肺孢子菌肺炎和进行性多灶性白质脑病风险升高的信号。

核心结论

  • 利妥昔单抗治疗天疱疮患者在初始12个月内COVID-19、寄生虫病和巨细胞病毒感染风险升高,且肺炎、骨髓炎和病毒感染风险在治疗1年后仍持续升高。
  • 未观察到结核、乙型肝炎病毒再激活、耶氏肺孢子菌肺炎和进行性多灶性白质脑病风险升高的信号。

研究设计与样本

  • 全球人群队列研究,比较利妥昔单抗组(n=963)与硫唑嘌呤或霉酚酸酯(MMF)组(n=963)的26种感染风险,采用倾向评分匹配优化可比性。

主要发现

  • 初始12个月内,利妥昔单抗组对比硫唑嘌呤或MMF组:COVID-19(HR 1.82,95%CI 1.06-3.14;P=0.028)、寄生虫病(HR 3.22,95%CI 1.04-9.97;P=0.032)、巨细胞病毒感染(HR 1.63,95%CI 1.04-2.58;P=0.033)风险升高。
  • 治疗≥12个月后,利妥昔单抗组对比硫唑嘌呤或MMF组:肺炎(HR 1.45,95%CI 1.00-2.10;P=0.047)、COVID-19(HR 1.87,95%CI 1.49-2.33;P<0.001)、骨髓炎(HR 2.42,95%CI 1.11-5.31;P=0.023)、单纯疱疹病毒感染(HR 2.06,95%CI 1.03-4.11;P=0.037)、巨细胞病毒感染(HR 1.63,95%CI 1.07-2.49;P=0.023)风险升高。

关键数值与推荐

  • 初始12个月内:COVID-19 HR 1.82(95%CI 1.06-3.14;P=0.028),寄生虫病 HR 3.22(95%CI 1.04-9.97;P=0.032),巨细胞病毒感染 HR 1.63(95%CI 1.04-2.58;P=0.033)。
  • 治疗≥12个月后:肺炎 HR 1.45(95%CI 1.00-2.10;P=0.047),COVID-19 HR 1.87(95%CI 1.49-2.33;P<0.001),骨髓炎 HR 2.42(95%CI 1.11-5.31;P=0.023),单纯疱疹病毒感染 HR 2.06(95%CI 1.03-4.11;P=0.037),巨细胞病毒感染 HR 1.63(95%CI 1.07-2.49;P=0.023)。

临床怎么用

  • 作者建议即使治疗1年后也应考虑肺炎球菌疫苗和抑制性抗病毒治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risk of infectious complications among patients with pemphigus managed by rituximab is yet to be precisely elucidated. OBJECTIVES: To evaluate the risk of infections in patients with pemphigus managed by rituximab vs. first-line corticosteroid-sparing agents [azathioprine and mycophenolate mofetil (MMF)]. METHODS: A global population-based cohort study compared patients with pemphigus initiating rituximab (n = 963) vs. azathioprine or MMF (n = 963) regarding the risk of 26 different infections. Propensity score matching was conducted to optimize comparability. RESULTS: During the initial 12 months following treatment, patients under rituximab experienced elevated risk of COVID-19 [hazard ratio (HR) 1.82, 95% confidence interval (CI) 1.06-3.14; P = 0.028], parasitic diseases (HR 3.22, 95% CI 1.04-9.97; P = 0.032) and cytomegalovirus (CMV) infection (HR 1.63, 95% CI 1.04-2.58; P = 0.033). When evaluating infections developing ≥ 12 months after drug initiation, rituximab was associated with greater risk of pneumonia (HR 1.45, 95% CI 1.00-2.10; P = 0.047), COVID-19 (HR 1.87, 95% CI 1.49-2.33; P < 0.001), osteomyelitis (HR 2.42, 95% CI 1.11-5.31; P = 0.023), herpes simplex virus (HR 2.06, 95% CI 1.03-4.11; P = 0.037) and CMV (HR 1.63, 95% CI 1.07-2.49; P = 0.023) infections. CONCLUSIONS: Within the first 12 months after treatment, patients under rituximab experience an elevated risk of COVID-19, parasitic and CMV infections. Rituximab is associated with pneumonia, osteomyelitis and viral diseases even beyond the first year after therapy. Pneumococcal vaccine and suppressive antiviral therapy should be considered even 1 year following therapy. There is no signal for elevated risk of tuberculosis, hepatitis B virus reactivation, Pneumocystis jiroveci pneumonia and progressive multifocal leukoencephalopathy.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Kridin K, Mruwat N, Amber KT, et al. Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. Br J Dermatol. 2023. PMID: 36763798. doi:10.1093/bjd/ljac118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。